مقالات پذیرفته شده در هفتمین کنگره بین المللی زیست پزشکی
Exploring the Therapeutic Potential of Copper-Cysteamine Nanoparticles Combined with Cisplatin in Cervical Cancer Treatment
Exploring the Therapeutic Potential of Copper-Cysteamine Nanoparticles Combined with Cisplatin in Cervical Cancer Treatment
Mahsa Ejtema,1Nahid Chegeni,2,*
1. Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur university of Medical Sciences, Ahvaz, Iran 2. Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur university of Medical Sciences, Ahvaz, Iran
Introduction: The field of combination therapy involving nanoparticles and conventional chemotherapy has recently gained considerable attention for its potential to improve therapeutic outcomes. Copper-Cysteamine nanoparticles (Cu-Cy NPs) have emerged as a promising candidate for various medical applications in nanotechnology, including cancer therapy. These nanoparticles possess unique properties that make them effective in combination with other treatment modalities. This study aims to investigate the effects of Cu-Cy nanoparticles in combination with cisplatin, a widely used chemotherapeutic agent, on HeLa human cervical cancer cells. The findings from this research will provide considerable insights into the potential of Cu-Cy nanoparticles as a novel approach to enhance the efficiency of chemotherapy.
Methods: In this investigation, we evaluated the cytotoxicity effect of Cu-Cy nanoparticles and cisplatin in various concentrations on HeLa cancer cells, both individually and in combination. To ensure sublethal individual treatment doses, we selected the IC25 dose of cisplatin based on preliminary dose-response experiments. Additionally, we conducted experiments to assess the combined effects of these substances. Cell viability was quantitatively determined using the MTT assay, while apoptosis was assessed using Annexin-V/PI staining, followed by flow cytometry analysis. Cell migration was evaluated through a wound healing assay.
Results: Our findings revealed a significant reduction in cell viability, with the combination treatment resulting in a cell survival rate of 54.89%. In contrast, cisplatin monotherapy and Cu-Cy NPs alone exhibited cell survival rates of 73.5% and 93.85%, respectively. The calculated combination index (CI) of 1.06 suggested a closely additive interaction between the two agents. Additionally, apoptosis analysis showed a significant increase in the apoptotic cell population (36.82%) in the combination group, compared to nanoparticle monotherapy (6.05%) and cisplatin monotherapy (15.54%). Furthermore, the combination treatment substantially inhibited cell migration compared to the control and other treatment groups.
Conclusion: In conclusion, our study highlights the potential of Cu-Cy NPs to enhance the therapeutic effectiveness of cisplatin in cancer treatment. The combination of Cu-Cy NPs with cisplatin resulted in a significant reduction in HeLa cell viability, exceeding the outcomes achieved with either agent alone. Moreover, the observed increase in apoptosis and inhibition of cell migration in the combination group further supports the potential clinical relevance of this approach. These findings underscore the importance of exploring nanoscale drug delivery systems in conjunction with conventional chemotherapy to maximize treatment outcomes.
While our study provides major insights, further investigation is required to elucidate the underlying molecular mechanisms and validate the translational potential of Cu-Cy NPs in combination with cisplatin in preclinical and clinical settings. This research represents a step forward in the ongoing effort to develop more effective and targeted cancer therapies.